First Trust Advisors
OVID icon

First Trust Advisors’s Ovid Therapeutics OVID Stock Holding History

First Trust Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-80,907
Closed -$174K – 2575
2022
Q2 		$174K Buy
80,907
+710
+0.9% +$1.72K ﹤0.01% 2407
2022
Q1 		$252K Sell
80,197
-4,655
-5% -$14.6K ﹤0.01% 2417
2021
Q4 		$272K Buy
84,852
+10,622
+14% +$36.4K ﹤0.01% 2406
2021
Q3 		$249K Sell
74,230
-35,950
-33% -$131K ﹤0.01% 2413
2021
Q2 		$431K Buy
110,180
+3,384
+3% +$13.4K ﹤0.01% 2310
2021
Q1 		$429K Buy
106,796
+8,573
+9% +$28.5K ﹤0.01% 2253
2020
Q4 		$227K Buy
98,223
+5,841
+6% +$27.2K ﹤0.01% 2256
2020
Q3 		$530K Buy
+92,382
New +$618K ﹤0.01% 2020

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Trust Advisors's OVID Position: Q3 2022 in Review

First Trust Advisors sold out of Ovid Therapeutics (OVID) in Q3 2022, closing a stake of 80,907 shares — an estimated $174K sold.

First Trust Advisors first reported a position in OVID in Q3 2020 and held it in 8 quarters. The position peaked at $530K in Q3 2020. 59 funds tracked by Wall St. Rank hold OVID as of Q3 2022.

  • First Trust Advisors reported no remaining Ovid Therapeutics position as of Q3 2022 after selling out during the quarter.
  • First Trust Advisors sold 80,907 Ovid Therapeutics shares in Q3 2022, an estimated $174K.
  • First Trust Advisors first reported a position in Ovid Therapeutics in Q3 2020 and held it in 8 quarters.
  • First Trust Advisors's Ovid Therapeutics position peaked at $530K in Q3 2020.
  • 59 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2022.

Based on First Trust Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.